Mercado15 pneumococcal conjugate vaccine V114 reaches major endpoint in Phase 2 clinical trial

today, msSAEast (MSD)company(http:// announcedthat the 15-price pneumococcal conjugate vaccine V114 developed by the company reached its main point in the(http://of phase 2 clinicaltrialsin infants withhealthy(http://at 6-12 weeks, the prevention of 13 serotypes covered by the two vaccines met the non-adverse standard compared to the existing 13-price pneumococcal conjugate vaccine (PCV13)It can also trigger an immune response in infants to two additional serotypes (22F and 33F)These results support the continuation of Phase 3 clinical trials of the vaccine by MercadonThe V114 vaccine developed by Mercado is a 15-price pneumococcal polysaccharide combination vaccine, which means that it allows vaccinated children to immunize against 15 common serotypes that cause pneumococcal disease, making it more effective to prevent pneumococcal disease in childrenThe V114 vaccine was awarded in January by theFDA(http://for the prevention of invasive pneumococcal disease (IPD) in pediatric patients aged 6 to 18In the randomized double-blind phase 2 clinical trial, called V114-008, 1,050 healthy infants were vaccinated against two different batches of V114, or PCV13results showed that the proportion of infants in the V114 group who met the WHO-accepted immune response standard for the serotype covered by both vaccines met the non-disadvantage standard compared to PCV13For the serotype 22F and 33F that PCV13 cannot prevent, the proportion of patients who met the immune response standard in the V114 group was more than 98% and 87%, respectively